SCHEMBL6441885

SCHEMBL6441885

N#Cc1c(Cl)nc(N)nc1OCc1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGMT P16455 2/20 0.53
SYK P43405 1/20 0.44
TLR7 Q9NYK1 3/20 0.41
TLR8 Q9NR97 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.39
PKM P14618 1/20 0.39
PARP10 Q53GL7 1/20 0.39
ADORA2A P29274 4/20 0.39
ADORA1 P30542 4/20 0.39
ADORA3 P0DMS8 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PIK3CD O00329 1/20 0.38
SQOR Q9Y6N5 1/20 0.37
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441414 0.91 MGMT (0.55) MGMTSYKTLR7TLR8SMN1; SMN2
SCHEMBL6443037 0.85 SQOR (0.51) MGMTTLR7TLR8ADORA2AADORA1
SCHEMBL6444882 0.83 MGMT (0.57) MGMTADORA2AADORA1CDK1CCNB1
SCHEMBL5041645 0.82 ADORA1 (0.57) MGMTADORA2AADORA1SQOR
SCHEMBL6441939 0.82 MGMT (0.48) MGMTSYKTLR7TLR8SMN1; SMN2
SCHEMBL6443675 0.82 MGMT (0.48) MGMTSYKTLR7TLR8SMN1; SMN2
SCHEMBL6441951 0.81 MGMT (0.47) MGMTSYKTLR7TLR8SMN1; SMN2
SCHEMBL6444489 0.79 ADORA2A (0.40) ADORA2AADORA1KDM4ESQOR
SCHEMBL5041663 0.78 ADORA2A (0.56) MGMTALDH1A1ADORA2AADORA1ADORA3
SCHEMBL5044782 0.78 ADORA2A (0.56) MGMTSMN1; SMN2ALDH1A1PKMADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 MGMT 3075/4885SYK 2739/4885TLR7 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.